Continued Improvement in Clinical Outcomes with Burosumab, a Fully Human Anti-FGF 23 Monoclonal Antibody: Results from a 3-year, Phase 2, Clinical Trial in Children with X-Linked Hypophosphatemia (XLH)
HORMONE RESEARCH IN PAEDIATRICS（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要